Aurinia Pharmaceuticals Inc (AUPH NASDAQ) stock market data APIs
$7.6595
-0.1(-1.3%)
as of July 3, 2025
Try our APIs with
free plan!
Aurinia Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
7.6595
Open
7.5617
High
7.5965
Low
7.3928
52 wk Range
5.195-10.67
Market Cap
1 025 M
P/E Ratio
28.1111
Shares Outstanding
135 M
Revenue
247 M
EPS
0.16
Beta
1.16
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 247 M
- EBITDA: 61 923 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: 0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
TD Cowen reiterates Buy rating on Aurinia Pharmaceuticals stock at $11
Investing.com - TD Cowen has reiterated a Buy rating and $11.00 price target on Aurinia Pharmaceuticals (NASDAQ:AUPH), a $1.16 billion market cap biotech company with a perfect Piotroski Score of 9 ac...
Leerink Partners reiterates Outperform rating on Aurinia stock after trial data
Investing.com - Leerink Partners has reiterated an Outperform rating and $10.00 price target on Aurinia Pharmaceuticals (NASDAQ:AUPH), a company currently showing strong financial health according to ...
Aurinia Pharma Reports Positive Results From Phase 1 Single-ascending-dose Study Of Aritinercept
(RTTNews) - Aurinia Pharmaceuticals (AUPH) announced positive results from a Phase 1 single-ascending-dose study of aritinercept, its dual inhibitor of B cell-activating factor and a proliferation-ind...
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to di...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
